Get the operating-system answer in writing
A SoftWriters requirements page last modified in December 2023 and reviewed July 18 described RxPertise 9.2 on Windows 10. It characterized Standard as a one-computer local installation—not server-client or remote multi-user—with periodic internet for updates and license checks, and warned that a 9.1 database upgraded to 9.2 could not return to 9.1. By July 30, the URL required support sign-in. These dated, configuration-specific details are not a current assurance for every edition.
Ordinary Windows 10 support ended October 14, 2025, while LTSC and Extended Security Update arrangements follow different paths. That proves neither an RxPertise security failure nor an end to vendor support. Ask the vendor and qualified IT advisers to name the Windows edition and servicing channel, approved RxPertise version, and ownership of patching, backup, recovery, endpoint protection, remote access, and hardware replacement.
A published transition example is not a deadline or parity claim
SoftWriters markets Framework RxP as a secure, cloud-based MRR platform; its AmPharm case study shows one customer moving from RxPertise to Framework RxP. Neither proves parity for another account. The case publishes no reusable field map, exclusions, reconciliation result, fee, downtime, or rollback detail, and AmPharm also changed staffing while using the broader Framework suite.
Ask SoftWriters for the account's maintenance term, support and escalation path, available updates, added-user or new-license status, migration scope, and any retirement milestone. A newer product and one customer story do not establish a public RxPertise retirement date or commit the vendor to the same roadmap elsewhere.
The live support trail answers a different question
The live Help Center offers a knowledge base, current-software downloads, tutorials, ticketing, update emails, and support contacts. Its Product ID lookup shows a license's maintenance status and end date. SoftWriters defines that as a renewal marker, not a public product-retirement deadline.
MHA's undated page says RxPertise serves existing and prospective users and receives enhancements. It neither demonstrates performance nor settles a license's status. Ask separately whether the account is maintained and supported, whether new customers can buy the product, and which product the vendor strategically prefers. Keep those answers separate.
Map the data route before comparing screens
Name the route before calling it an integration. FrameworkExchange is described as letting RxPertise retrieve FrameworkLTC data in real time. The separate Consulting Software Interface is described as exporting demographics and orders from FrameworkLTC into a DAT file for third-party consulting software. Neither statement demonstrates an RxPertise review-history export or a broader catalog of EHR, eMAR, laboratory, and dispensing connections.
Reproduce the account's route on paper and in a test: identify the source and version, participating facilities, fields, direction, refresh behavior, identity matching, corrections, visible failures, retained history, and owner. A replacement with a newer interface can still fail acceptance if it loses a dependable data path or makes review, handoff, and reporting less workable.
Define migration in layers
Do not accept resident totals as the conversion test. Sample six evidence layers instead: facility and resident master data; medication and clinical context; recommendation, response, and status history; attachments and report artifacts; templates and facility configuration; and provenance including author, recipient, source identifier, and timestamps. For each layer, record whether it will be converted, archived for reference, rebuilt, or unavailable.
Then stage the edge cases that remain active at cutover: open recommendations, urgent items, reports coming due, coverage handoffs, and corrections not yet reconciled. Acceptance needs a named authoritative system, freeze point, late-change procedure, production approver, and rollback threshold before live work moves.
Get seven answers before choosing continuity or migration
- Identity evidence: Record the installed edition, version, Product ID, database, operating system, and deployment pattern rather than testing against a generic RxPertise description.
- Support evidence: Obtain the maintenance term, available updates, response expectations, escalation route, and support dates that apply to this Product ID.
- Commercial evidence: Confirm whether the practice may add users, devices, facilities, or licenses and request the current terms for each change.
- Data-route evidence: Demonstrate what supplies resident and medication information today and the exact mechanism proposed to replace that flow.
- Exit evidence: Open samples of the structured data, readable reports, attachments, identifiers, configuration, and audit information the account can export.
- Conversion evidence: Document what transfers unchanged, what changes meaning, what stays behind, who clears each exception, and which fees apply.
- Acceptance evidence: Reconcile samples covering active and inactive residents, pending responses, GDR history, corrected reports, attachments, and multiple authors before approving cutover.
Choose from demonstrated operating fit
Use one synthetic resident as the observable acceptance script in both systems. Refresh the source data, complete the review, route a recommendation, capture response and rationale, retain follow-up, correct a released report, hand work to a covering user, and open the export. Score what happened on screen and in the output separately from a vendor description or planned configuration.
That test may support continuity for one practice and Framework RxP or another replacement for another. The evidence threshold is the same either way: maintained account support, a viable endpoint, a dependable data route, and reconciled conversion results. A broad brand-status label cannot substitute for those findings.